Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries

Inclusion Criteria: 1. Informed consent obtained prior to any trial activities. 2. Patients, male or female between 21 and 80 years of age, with no significant co-morbidities (see exclusion criteria). 3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI flow 0 to 1. Exclusion Criteria: 1. Patient unable to give informed consent. 2. Current participation in another study with any investigational drug or device. 3. Factors making follow-up and/or repeat angiography difficult or unlikely. 4. Contra-indication to emergency artery by pass surgery. 5. Lack of surgical backup. 6. Contra-indication to treatment with Aspirin, or Clopidogrel and/or Heparin. 7. Lesion \> 40mm in length (both calcified lesion and adjacent thrombus). 8. Treated vessel referenced diameter less than 2.5 mm. 9. Visualization of the distal lumen less than the Rentrop Classification Grade 2 collateralization. 10. Non-visible entry point of target lesion. 11. Totally occluded bypass graft as target vessel. 12. Acute MI less than 1 week before procedure. 13. Patient has significant LV dysfunction, 35% LVEF or less. 14. Patient with cancer or other sever chronic disease with life expectance of 2 years. 15. Patient has chronic renal failure with serum creatinine ≥2. 16. Hemoglobin ≤11. 17. Patient is known or suspected not to tolerate the contrast agent. 18. Morbid Obesity (BMI \> 40). 19. Drug abuse or alcoholism. 20. Patients under custodial care. 21. Pregnant women or women with childbearing potential with a positive pregnancy test at the time of procedure.